Dr. John Cush RheumNow
5 years 6 months ago
Follow the hashtag #RNL2021 for all RheumNow Live coverage today and tomorrow!
Dr. John Cush RheumNow
5 years 6 months ago
RheumNow Live has started! #RNL2021 https://t.co/CrNqnnKqUy
Dr. John Cush RheumNow
5 years 6 months ago
Metanalysis reveals significant heterogeneity in defining Refractory Disease in RA and polyarticular JIA. Should include: 1) Resistance to multiple drugs w/ different MOAs (≥2bDMARDs) and 2) Persistent symptoms and disease activity https://t.co/CL6Mr3cs7J
Dr. John Cush RheumNow
5 years 6 months ago
News Feature: Are You a Super Rheum?
https://t.co/LsGpFNXlkp https://t.co/Q9iojEQNqL
Dr. John Cush RheumNow
5 years 6 months ago
Top 4 arthritis types that significantly increase the risk of CVA: 1) RA (RR=1.38), 2) ankylosing spondylitis (RR=1.49), 3) psoriatic arthritis (RR=1.33) & gout (RR=1.4). With these, the risk was higher in younger (<45 yrs) (RR = 1.46), not older (>65) https://t.co/Snb6OrtZJH
There are no current FDA approved therapies for rheumatoid arthritis associated interstitial lung disease (RA-ILD) or bronchiectasis, but a recent retrospective cohort study showed equivalent outcomes when RA-ILD patients were treated with either rituximab or janus kinase inhibitors.
Dr. John Cush RheumNow
5 years 6 months ago
NAFLD, NASH and Risks with DMARDs and MTX
https://t.co/LYV9WycEjz https://t.co/Vx0jvhjCsd
Dr. John Cush RheumNow
5 years 6 months ago
Kiniksa announced Arcalyst (rilonacept) has been FDA-approved for the treatment of recurrent pericarditis. Rilonacept, an IL-1 inhibitor, also FDA approved for CAPS (Cryopyrin-Assoc Periodic Syndr) & DIRA (Defic IL-1 Recept Antag) https://t.co/erpiyuhsAv https://t.co/xp764WkWEI
Dr. John Cush RheumNow
5 years 6 months ago
News Feature: MDA-5 Antibodies and Juvenile Dermatomyositis
https://t.co/vxyXZyO0gs https://t.co/GgzhnhlmdR
Dr. John Cush RheumNow
5 years 6 months ago
SPIRIT‐P3 RCT treated biologic‐naive PsA with ixekizumab x36 wks; those w/ MDA x 3 mos were randomized to continue or withdraw IXE (blinded). There were significantly more relapses when IXE was stopped; most regained control when started https://t.co/lhQ8X1Ef48
Dr. John Cush RheumNow
5 years 6 months ago
RCT shows Stepped Exercise Program to be effective in Knee Osteoarthritis. VAMC study of 345 knee OA pts given either STEP-KOA (internet based progr) or an arthritis education (control). WOMAC scores at 9 mos were 6.8 points lower in the STEP-KOA group.https://t.co/EuoPyJkTif
Dr. Jack Cush rants on the journal reports, news and FDA actions featured this past week on RheumNow.com.
Dr. John Cush RheumNow
5 years 6 months ago
There's still time to sign up. Attend RheumNow Live this weekend. We have a robust schedule planned with top professional.
https://t.co/LJ3qClHTKh
Dr. John Cush RheumNow
5 years 6 months ago
Hydroxychloroquine studied vs Vitamin C (PBO) prophylaxis to households (n=671) exposed to COVID-19. 89% were COVD1-9 test neg at baseline. HCQ did not protect against progression to COVID (53 vs 45 events; adj HR, 1.10 [95% CI, 0.73 to 1.66]. A vit C Win! https://t.co/S5qjdIYaXq
